{"a":[{"_":"Supernus, Indivior merge to create CNS-focused company and expand BD opportunities","$":{"href":"/pharma/supernus-indivior-merge-create-cns-focused-company-and-expand-bd-opportunities","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Supernus and Indivior have agreed to merge in an all-stock transaction to create a CNS-focused biopharma company with anticipated combined revenue of $2.2 billion and $125 million in cost savings.
Financial Highlights
Revenue
$2.2 billion
Outcome Details
All-stock merger transaction to form new CNS-focused biopharma
Importance:8/10
Sentiment:
0.70
M&ACNS FocusMergerCost SynergiesAll-Stock Deal
Read the original article
Published by FiercePharma on August 3, 2026 11:00 AM